SGMO sangamo.com: Total Stockholders' Equity

Sangamo Therapeutics (SGMO) ensures the preservation of biomaterials through a strict temperature regime during transportation. The brand possesses a powerful patent portfolio and recognition from industry leaders in the field of genome editing. Additionally, automated systems are being implemented in sterile workshops to minimize errors during drug formulation. The current indicator is -0.02. The market value dynamics of the asset on the GURU.Markets platform clearly demonstrate the company's market positions.

For Sangamo Therapeutics (SGMO), a leader in genome editing with a unique patent portfolio, book capitalization reflects the real value of net assets minus all liabilities. By analyzing the equity level based on book value, an investor sees the actual financial foundation of the business. This metric measures the company's intrinsic value, separating market noise from accumulated capital. Growth in this indicator confirms the capitalization of intellectual property, serving as a key marker of the biopharmaceutical startup's long-term sustainability.